POZEN elects Dr Martin Nicklasson to board
This article was originally published in Scrip
POZEN has elected Dr Martin Nicklasson, a senior partner at independent consultancy company Nicklasson Life Science, to its board of directors. Dr Nicklasson serves on the boards of the Stockholm Chamber of Commerce and the Heart and Lung Foundation of Sweden. He was previously president and CEO of Biovitrum and Swedish Orphan Biovitrum.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.